Standout Papers

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxor... 2004 2026 2011 2018 1.3k
  1. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer (2004)
    E O’Brien, Nely Wigler et al. Annals of Oncology

Immediate Impact

3 by Nobel laureates 10 from Science/Nature 62 standout
Sub-graph 1 of 20

Citing Papers

Metabolic reprogramming in cancer: Mechanisms and therapeutics
2023 Standout
Flood hazard potential reveals global floodplain settlement patterns
2023 Standout

Works of R. Rosso being referenced

Uncertainty Assessment of Regionalized Flood Frequency Estimates
2001
The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force.
1999

Author Peers

Author Last Decade Papers Cites
R. Rosso 2909 3072 2138 237 10.2k
Atiqur Rahman 2148 3156 889 289 10.8k
Robert Olson 947 2454 394 313 16.5k
Peter Lamb 1864 4180 363 175 10.0k
Dongmei Chen 373 1593 498 314 8.7k
Xiaoping Liu 362 4948 325 481 14.4k
David R. Turner 426 549 465 214 7.4k
Lei Huang 257 759 895 275 13.0k
Paul D. Wagner 495 1039 984 135 5.7k
Rui Jin 392 1109 590 334 9.5k
Ross Brown 863 2516 684 186 9.1k

All Works

Loading papers...

Rankless by CCL
2026